{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T23:56:10Z","timestamp":1790898970446,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"vor","delay-in-days":88,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-16455-8","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:24:33Z","timestamp":1783297473000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Genomic landscape of triple-negative breast cancer in South Asian populations: a systematic review"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2517-8994","authenticated-orcid":false,"given":"Shantanu","family":"Bhattacharyya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3138-8476","authenticated-orcid":false,"given":"Jitu V.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9043-448X","authenticated-orcid":false,"given":"Abhishek","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arunima","family":"Deep","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. N. U.","family":"Bhuvan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9194-3829","authenticated-orcid":false,"given":"Sivaramakrishnan","family":"Ramachandiran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh Kumar","family":"Garanayak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"issue":"11","key":"16455_CR1","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","volume":"13","author":"G Bianchini","year":"2016","unstructured":"Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016;13(11):674\u201390. https:\/\/doi.org\/10.1038\/nrclinonc.2016.66.","journal-title":"Nat Rev Clin Oncol"},{"issue":"20","key":"16455_CR2","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1056\/NEJMra1001389","volume":"363","author":"WD Foulkes","year":"2010","unstructured":"Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363(20):1938\u201348. https:\/\/doi.org\/10.1056\/NEJMra1001389.","journal-title":"N Engl J Med"},{"issue":"2","key":"16455_CR3","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1158\/2159-8290.CD-18-1177","volume":"9","author":"AC Garrido-Castro","year":"2019","unstructured":"Garrido-Castro AC, Lin NU, Polyak K. Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment. Cancer Discov. 2019;9(2):176\u201398. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-1177.","journal-title":"Cancer Discov"},{"issue":"7","key":"16455_CR4","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1172\/JCI45014","volume":"121","author":"BD Lehmann","year":"2011","unstructured":"Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121(7):2750\u201367. https:\/\/doi.org\/10.1172\/JCI45014.","journal-title":"J Clin Invest"},{"key":"16455_CR5","doi-asserted-by":"publisher","unstructured":"Schmid P, Cortes J, Pusztai L, McArthur H, K\u00fcmmel S, Bergh J, et al. KEYNOTE-522 Investigators. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020a;382(9):810\u2013821. https:\/\/doi.org\/10.1056\/NEJMoa1910549","DOI":"10.1056\/NEJMoa1910549"},{"issue":"22","key":"16455_CR6","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","volume":"379","author":"P Schmid","year":"2018","unstructured":"Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379(22):2108\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1809615.","journal-title":"N Engl J Med"},{"issue":"16","key":"16455_CR7","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","volume":"384","author":"A Bardia","year":"2021","unstructured":"Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer (ASCENT). N Engl J Med. 2021;384(16):1529\u201341. https:\/\/doi.org\/10.1056\/NEJMoa2028485.","journal-title":"N Engl J Med"},{"key":"16455_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2026.03.008","author":"R Dent","year":"2026","unstructured":"Dent R, Shao Z, Schmid P, Pernas S, O\u2019Shaughnessy J, Cescon DW, et al. Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial. Ann Oncol. 2026. https:\/\/doi.org\/10.1016\/j.annonc.2026.03.008.","journal-title":"Ann Oncol"},{"issue":"3","key":"16455_CR9","first-page":"362","volume":"22","author":"C Denkert","year":"2021","unstructured":"Denkert C, von Minckwitz G, Brase JC, Sinn BV, Gade S, Kronenwett R, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis. Lancet Oncol. 2021;22(3):362\u201374.","journal-title":"Lancet Oncol"},{"issue":"7418","key":"16455_CR10","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nature11412","volume":"490","author":"CGA Network","year":"2012","unstructured":"Network CGA. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61\u201370. https:\/\/doi.org\/10.1038\/nature11412.","journal-title":"Nature"},{"issue":"5","key":"16455_CR11","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1002\/ijc.24831","volume":"126","author":"E Lopez-Knowles","year":"2010","unstructured":"Lopez-Knowles E, O\u2019Toole SA, McNeil CM, Millar EK, Qiu MR, Crea P, et al. PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality. Int J Cancer. 2010;126(5):1121\u201331. https:\/\/doi.org\/10.1002\/ijc.24831.","journal-title":"Int J Cancer"},{"issue":"2","key":"16455_CR12","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nrc.2015.21","volume":"16","author":"CJ Lord","year":"2016","unstructured":"Lord CJ, Ashworth A. BRCAness revisited. Nat Rev Cancer. 2016;16(2):110\u201320. https:\/\/doi.org\/10.1038\/nrc.2015.21.","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"16455_CR13","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1706450","volume":"377","author":"M Robson","year":"2017","unstructured":"Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377(6):523\u201333. https:\/\/doi.org\/10.1056\/NEJMoa1706450.","journal-title":"N Engl J Med"},{"issue":"15","key":"16455_CR14","doi-asserted-by":"publisher","first-page":"3764","DOI":"10.1158\/1078-0432.CCR-15-2477","volume":"22","author":"ML Telli","year":"2016","unstructured":"Telli ML, Timms KM, Reid J, Hennessy B, Mills GB, Jensen KC, et al. Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer. Clin Cancer Res. 2016;22(15):3764\u201373. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2477.","journal-title":"Clin Cancer Res"},{"issue":"6330","key":"16455_CR15","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1126\/science.aam7344","volume":"355","author":"CJ Lord","year":"2017","unstructured":"Lord CJ, Ashworth A. PARP inhibitors: synthetic lethality in the clinic. Science. 2017;355(6330):1152\u20138. https:\/\/doi.org\/10.1126\/science.aam7344.","journal-title":"Science"},{"issue":"4","key":"16455_CR16","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/nm.4292","volume":"23","author":"H Davies","year":"2017","unstructured":"Davies H, Glodzik D, Morganella S, Yates LR, Staaf J, Zou X, et al. HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures. Nat Med. 2017;23(4):517\u201325. https:\/\/doi.org\/10.1038\/nm.4292.","journal-title":"Nat Med"},{"issue":"7605","key":"16455_CR17","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature17676","volume":"534","author":"S Nik-Zainal","year":"2016","unstructured":"Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D, Zou X, et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature. 2016;534(7605):47\u201354. https:\/\/doi.org\/10.1038\/nature17676.","journal-title":"Nature"},{"issue":"3","key":"16455_CR18","doi-asserted-by":"publisher","first-page":"e393","DOI":"10.1016\/j.clbc.2017.07.013","volume":"18","author":"KK Thakur","year":"2018","unstructured":"Thakur KK, Bordoloi D, Kunnumakkara AB. alarming burden of triple-negative breast cancer in India. Clin Breast Cancer. 2018;18(3):e393\u20139. https:\/\/doi.org\/10.1016\/j.clbc.2017.07.013.","journal-title":"Clin Breast Cancer"},{"key":"16455_CR19","unstructured":"Saxena S, Rekhi B, Bansal A, Bagga A, Chintamani, Murthy NS. Clinico-morphological patterns of breast cancer including triple-negative breast cancer in a tertiary care centre in India. Indian J Cancer. 2012;49(4):402\u2013408."},{"issue":"7624","key":"16455_CR20","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/538161a","volume":"538","author":"AB Popejoy","year":"2016","unstructured":"Popejoy AB, Fullerton SM. Genomics is failing on diversity. Nature. 2016;538(7624):161\u20134. https:\/\/doi.org\/10.1038\/538161a.","journal-title":"Nature"},{"issue":"1","key":"16455_CR21","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.cell.2019.02.048","volume":"177","author":"G Sirugo","year":"2019","unstructured":"Sirugo G, Williams SM, Tishkoff SA. The missing diversity in human genetic studies. Cell. 2019;177(1):26\u201331. https:\/\/doi.org\/10.1016\/j.cell.2019.02.048.","journal-title":"Cell"},{"issue":"4","key":"16455_CR22","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1007\/s11033-022-07129-2","volume":"49","author":"T Rajagopal","year":"2022","unstructured":"Rajagopal T, Seshachalam A, Jothi A, Rathnam KK, Talluri S, Venkatabalasubranian S, et al. Analysis of pathogenic variants in BRCA1 and BRCA2 genes using next-generation sequencing in women with triple negative breast cancer from South India. Mol Biol Rep. 2022;49(4):3025\u201332. https:\/\/doi.org\/10.1007\/s11033-022-07129-2.","journal-title":"Mol Biol Rep"},{"issue":"1","key":"16455_CR23","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1186\/s12885-016-2698-y","volume":"16","author":"MU Rashid","year":"2016","unstructured":"Rashid MU, Muhammad N, Bajwa S, Faisal S, Tahseen M, Bermejo JL, et al. High prevalence and predominance of BRCA1 germline mutations in Pakistani triple-negative breast cancer patients. BMC Cancer. 2016;16(1):673. https:\/\/doi.org\/10.1186\/s12885-016-2698-y.","journal-title":"BMC Cancer"},{"issue":"10","key":"16455_CR24","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1097\/PAI.0000000000001231","volume":"32","author":"P Gupta","year":"2024","unstructured":"Gupta P, Thakur T, Chadda A, Irinike S, Khare S, Bal A. A pilot study on BRCA1\/2 and PI3K mutations across subtypes of triple-negative breast cancer in North Indian population. Appl Immunohistochem Mol Morphol. 2024;32(10):462\u20138. https:\/\/doi.org\/10.1097\/PAI.0000000000001231.","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"2","key":"16455_CR25","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s10549-024-07501-9","volume":"209","author":"L Pachuau","year":"2025","unstructured":"Pachuau L, Lalremmawia H, Ralte L, Vanlalpeka J, Pautu JL, Chenkual S, et al. Uncovering novel pathogenic variants and pathway mutations in triple-negative breast cancer among the endogamous Mizo tribe. Breast Cancer Res Treat. 2025;209(2):375\u201387. https:\/\/doi.org\/10.1007\/s10549-024-07501-9.","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"16455_CR26","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1007\/s11033-018-4307-4","volume":"45","author":"M Aravind Kumar","year":"2018","unstructured":"Aravind Kumar M, Naushad SM, Narasimgu N, Nagaraju Naik S, Kadali S, Shanker U, et al. Whole exome sequencing of breast cancer (TNBC) cases from India: association of MSH6 and BRIP1 variants with TNBC risk and oxidative DNA damage. Mol Biol Rep. 2018;45(5):1413\u20139. https:\/\/doi.org\/10.1007\/s11033-018-4307-4.","journal-title":"Mol Biol Rep"},{"issue":"4","key":"16455_CR27","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1111\/tbj.13609","volume":"26","author":"MA Naeem","year":"2020","unstructured":"Naeem MA, Shah TH, Zafar N, Khan M, Bhutto AA, Rabbani S. Detection of JAK2 gene mutation in Pakistani women with triple-negative breast cancer. Breast J. 2020;26(4):829\u201330. https:\/\/doi.org\/10.1111\/tbj.13609.","journal-title":"Breast J"},{"key":"16455_CR28","doi-asserted-by":"publisher","unstructured":"Rashid MU, Muhammad N, Khan FA, Hamann U. Absence of the FANCM c.5101C>T mutation in BRCA1\/2-negative triple-negative breast cancer patients from Pakistan. Breast Cancer Res Treat. 2015;152(1):229\u2013230. https:\/\/doi.org\/10.1007\/s10549-015-3457-5","DOI":"10.1007\/s10549-015-3457-5"},{"key":"16455_CR29","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.cancergen.2025.06.004","volume":"296\u2013297","author":"J John","year":"2025","unstructured":"John J, Bapat A, Gahlaut S, Luke N, Kumar R, Thakur Y, et al. Assessing germline mutational profile and its clinicopathological associations in triple negative breast cancer. Cancer Genet. 2025;296\u2013297:65\u201375. https:\/\/doi.org\/10.1016\/j.cancergen.2025.06.004.","journal-title":"Cancer Genet"},{"issue":"25","key":"16455_CR30","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","volume":"384","author":"ANJ Tutt","year":"2021","unstructured":"Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med. 2021;384(25):2394\u2013405. https:\/\/doi.org\/10.1056\/NEJMoa2105215.","journal-title":"N Engl J Med"},{"issue":"3","key":"16455_CR31","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"16455_CR32","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1200\/JCO.19.00368","volume":"38","author":"P Schmid","year":"2020","unstructured":"Schmid P, Abraham J, Chan S, Wheatley D, Brunt AM, Nemsadze G, et al. Capivasertib plus paclitaxel versus placebo plus paclitaxel in metastatic triple-negative breast cancer. J Clin Oncol. 2020;38(5):423\u201333. https:\/\/doi.org\/10.1200\/JCO.19.00368.","journal-title":"J Clin Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16455-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16455-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16455-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T23:37:06Z","timestamp":1790897826000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16455-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16455"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16455-8","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,6]]},"assertion":[{"value":"16 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable. This systematic review is based exclusively on previously published studies; ethical approval and informed consent were not required.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1167"}}